• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肌肉减少型内脏肥胖与肝硬化急性病患者肝移植后死亡率的增加相关。

Sarcopenic visceral obesity is associated with increased post-liver transplant mortality in acutely ill patients with cirrhosis.

机构信息

Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, California, USA.

Division of Gastroenterology and Liver Unit, Department of Medicine, University of Alberta, Edmonton, AB, Canada.

出版信息

Am J Transplant. 2022 Sep;22(9):2195-2202. doi: 10.1111/ajt.17079. Epub 2022 May 13.

DOI:10.1111/ajt.17079
PMID:35486028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9427718/
Abstract

"Sarcopenic obesity" refers to a condition of low muscle mass in the context of obesity, though may be difficult to assess in patients with cirrhosis who are acutely ill. We aimed to define sarcopenic visceral obesity (SVO) using CT-based skeletal muscle index (SMI) and visceral-to-subcutaneous adipose tissue ratio (VSR) to examine its association with post-transplant mortality. We analyzed 116 adult inpatients with cirrhosis who were urgently listed and transplanted between 1/2005 and 12/2017 at 4 North American transplant centers. SVO was defined as patients with sarcopenia (SMI <50 cm /m in men and <39 cm /m in women) and visceral obesity (VSR ≥ 1.54 in men and ≥1.37 in women). The percentage who met criteria for sarcopenia, visceral obesity, and SVO were 45%, 42%, and 20%, respectively. Cumulative rates of post-transplant mortality were higher in patients with SVO compared to patients with sarcopenia or visceral obesity alone at 36 months (39% vs. 14% vs. 8%) [logrank p = .01]. In univariable regression, SVO was associated with post-transplant mortality (HR 2.92, 95%CI 1.04-8.23) and remained significant after adjusting for age, sex, diabetes, encephalopathy, hepatocellular carcinoma, and MELD-Na (HR 3.50, 95%CI 1.10-11.15). In conclusion, SVO is associated with increased post-transplant mortality in acutely ill patients with cirrhosis.

摘要

"肌少症性肥胖"是指肥胖患者的肌肉量低,但对于患有急性疾病的肝硬化患者,可能难以评估。我们旨在使用基于 CT 的骨骼肌指数 (SMI) 和内脏脂肪与皮下脂肪组织比 (VSR) 来定义肌少性内脏肥胖 (SVO),并检查其与移植后死亡率的关系。我们分析了 2005 年 1 月至 2017 年 12 月在北美 4 个移植中心紧急列出并进行移植的 116 名成年肝硬化住院患者。将 SVO 定义为患有肌少症 (男性 SMI<50cm/m,女性 SMI<39cm/m) 和内脏肥胖 (男性 VSR≥1.54,女性 VSR≥1.37) 的患者。符合肌少症、内脏肥胖和 SVO 标准的患者比例分别为 45%、42%和 20%。在 36 个月时,SVO 患者的移植后死亡率高于仅患有肌少症或内脏肥胖的患者,分别为 39%、14%和 8%[logrank p=0.01]。在单变量回归中,SVO 与移植后死亡率相关 (HR 2.92,95%CI 1.04-8.23),在调整年龄、性别、糖尿病、肝性脑病、肝细胞癌和 MELD-Na 后仍然显著 (HR 3.50,95%CI 1.10-11.15)。总之,SVO 与肝硬化急性疾病患者的移植后死亡率增加有关。

相似文献

1
Sarcopenic visceral obesity is associated with increased post-liver transplant mortality in acutely ill patients with cirrhosis.肌肉减少型内脏肥胖与肝硬化急性病患者肝移植后死亡率的增加相关。
Am J Transplant. 2022 Sep;22(9):2195-2202. doi: 10.1111/ajt.17079. Epub 2022 May 13.
2
CT-quantified sarcopenic visceral obesity is associated with poor transplant waitlist mortality in patients with cirrhosis.CT 定量的肌肉减少性内脏肥胖与肝硬化患者移植等待名单死亡率差相关。
Liver Transpl. 2023 May 1;29(5):476-484. doi: 10.1097/LVT.0000000000000010. Epub 2023 Jan 3.
3
Sarcopenia Predicts Post-transplant Mortality in Acutely Ill Men Undergoing Urgent Evaluation and Liver Transplantation.肌肉减少症预测急性危重症男性接受紧急评估和肝移植后的移植后死亡率。
Transplantation. 2019 Nov;103(11):2312-2317. doi: 10.1097/TP.0000000000002741.
4
Visceral Adipose Tissue Inflammation and Radiographic Visceral-to-Subcutaneous Adipose Tissue Ratio in Patients with Cirrhosis.肝硬化患者内脏脂肪组织炎症与影像学内脏-皮下脂肪组织比值。
Dig Dis Sci. 2022 Jul;67(7):3436-3444. doi: 10.1007/s10620-021-07099-8. Epub 2021 Jun 16.
5
Impact of sarcopenic obesity on outcomes in patients undergoing living donor liver transplantation.肌少症性肥胖对活体供肝移植患者结局的影响。
Clin Nutr. 2019 Oct;38(5):2202-2209. doi: 10.1016/j.clnu.2018.09.019. Epub 2018 Sep 28.
6
Visceral adiposity in cirrhosis: Association with disease severity and impact of liver transplantation.肝硬化内脏性肥胖:与疾病严重程度的关系及肝移植的影响。
Hepatol Commun. 2023 May 15;7(6). doi: 10.1097/HC9.0000000000000113. eCollection 2023 Jun 1.
7
Prognostic value of sarcopenic visceral obesity in hepatocellular carcinoma treated with TACE.TACE 治疗肝细胞癌中肌少性内脏肥胖的预后价值。
Medicine (Baltimore). 2023 Jul 7;102(27):e34292. doi: 10.1097/MD.0000000000034292.
8
Visceral adiposity and inflammatory bowel disease.内脏肥胖与炎症性肠病。
Int J Colorectal Dis. 2021 Nov;36(11):2305-2319. doi: 10.1007/s00384-021-03968-w. Epub 2021 Jun 9.
9
Impact of sarcopenic obesity on 30-day mortality in critically ill patients with intra-abdominal sepsis.腹腔脓毒症危重症患者肌少症性肥胖对 30 天死亡率的影响。
J Crit Care. 2018 Aug;46:50-54. doi: 10.1016/j.jcrc.2018.03.019. Epub 2018 Mar 16.
10
Association between Abdominal CT Measurements of Body Composition before Deceased Donor Liver Transplant with Posttransplant Outcomes.腹部 CT 测量的人体成分与尸体供肝移植后移植结局的关系。
Radiology. 2023 Mar;306(3):e212403. doi: 10.1148/radiol.212403. Epub 2022 Oct 25.

引用本文的文献

1
Effect of sarcopenia on the survival of patients undergoing liver transplantation: a meta-analysis.肌肉减少症对肝移植患者生存的影响:一项荟萃分析。
Surg Today. 2025 Jun;55(6):803-813. doi: 10.1007/s00595-025-03008-y. Epub 2025 Feb 10.
2
Sarcopenic obesity is significantly associated with poorer overall survival after liver transplantation: a systematic review and meta-analysis.肌肉减少性肥胖与肝移植后总体生存率较差显著相关:一项系统评价和荟萃分析。
Front Nutr. 2024 Dec 16;11:1387602. doi: 10.3389/fnut.2024.1387602. eCollection 2024.
3
Sarcopenic obesity in patients awaiting liver transplant: Unique challenges for nutritional recommendations.

本文引用的文献

1
Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.肝硬化患者的营养不良、衰弱和肌肉减少症:美国肝病研究协会2021年实践指南
Hepatology. 2021 Sep;74(3):1611-1644. doi: 10.1002/hep.32049.
2
OPTN/SRTR 2019 Annual Data Report: Liver.OPTN/SRTR 2019 年度数据报告:肝脏。
Am J Transplant. 2021 Feb;21 Suppl 2:208-315. doi: 10.1111/ajt.16494.
3
A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.北美专家关于肝移植中肌肉减少症的观点声明。
等待肝移植患者的肌少症性肥胖:营养建议面临的独特挑战。
World J Transplant. 2024 Jun 18;14(2):90202. doi: 10.5500/wjt.v14.i2.90202.
4
Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse.肝硬化治疗中易被忽视的因素:病情恶化的隐匿元凶
Prz Gastroenterol. 2024;19(1):6-17. doi: 10.5114/pg.2024.136361. Epub 2024 Mar 14.
5
Sarcopenic obesity is associated with adverse outcomes after kidney transplantation: a retrospective cohort study.肌肉减少性肥胖与肾移植后不良结局相关:一项回顾性队列研究。
Int Urol Nephrol. 2024 Aug;56(8):2565-2575. doi: 10.1007/s11255-024-03982-1. Epub 2024 Mar 2.
6
Enhancing ACLF prediction by integrating sarcopenia assessment and frailty in liver transplant candidates on the waiting list.通过整合肌肉减少症评估和等待名单上肝移植候选者的衰弱情况来增强慢加急性肝衰竭的预测。
JHEP Rep. 2023 Dec 19;6(3):100985. doi: 10.1016/j.jhepr.2023.100985. eCollection 2024 Mar.
7
The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy.MAPS-CRAFITY 评分:一种新的预测工具,可预测不可切除的肝细胞癌接受靶向治疗联合免疫治疗的疗效。
Hepatol Int. 2023 Dec;17(6):1519-1531. doi: 10.1007/s12072-023-10580-3. Epub 2023 Sep 14.
8
Body composition and short-term mortality in patients critically ill with acute-on-chronic liver failure.慢性肝衰竭急性发作重症患者的身体组成与短期死亡率
JHEP Rep. 2023 Apr 7;5(8):100758. doi: 10.1016/j.jhepr.2023.100758. eCollection 2023 Aug.
9
Liver transplantation in the patient with physical frailty.体质虚弱患者的肝移植。
J Hepatol. 2023 Jun;78(6):1105-1117. doi: 10.1016/j.jhep.2023.03.025.
10
Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease.非酒精性脂肪性肝病/代谢相关脂肪性肝病中的肌少症骨量减少症:慢性肝病中一个被低估的临床问题。
Int J Mol Sci. 2023 Apr 19;24(8):7517. doi: 10.3390/ijms24087517.
Hepatology. 2019 Nov;70(5):1816-1829. doi: 10.1002/hep.30828. Epub 2019 Aug 19.
4
Sarcopenia Predicts Post-transplant Mortality in Acutely Ill Men Undergoing Urgent Evaluation and Liver Transplantation.肌肉减少症预测急性危重症男性接受紧急评估和肝移植后的移植后死亡率。
Transplantation. 2019 Nov;103(11):2312-2317. doi: 10.1097/TP.0000000000002741.
5
Impact of sarcopenic obesity on outcomes in patients undergoing living donor liver transplantation.肌少症性肥胖对活体供肝移植患者结局的影响。
Clin Nutr. 2019 Oct;38(5):2202-2209. doi: 10.1016/j.clnu.2018.09.019. Epub 2018 Sep 28.
6
Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis.低皮下脂肪量与肝硬化女性患者的死亡率升高相关。
J Hepatol. 2018 Sep;69(3):608-616. doi: 10.1016/j.jhep.2018.04.015. Epub 2018 Apr 28.
7
Impact of sarcopenic overweight on the outcomes after living donor liver transplantation.肌少性超重对活体肝移植术后结局的影响。
Hepatobiliary Surg Nutr. 2017 Dec;6(6):367-378. doi: 10.21037/hbsn.2017.02.02.
8
Impact of Sarcopenic Obesity on Outcomes in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma.肌少症性肥胖对肝细胞癌患者肝切除术后结局的影响。
Ann Surg. 2019 May;269(5):924-931. doi: 10.1097/SLA.0000000000002555.
9
Liver Transplantation in the Obese Cirrhotic Patient.肥胖肝硬化患者的肝移植
Transplantation. 2017 Oct;101(10):2288-2296. doi: 10.1097/TP.0000000000001794.
10
Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis.隐匿性肌肉减少症:低估非酒精性脂肪性肝炎肌肉功能障碍的风险和后果。
Hepatology. 2017 Dec;66(6):2055-2065. doi: 10.1002/hep.29420. Epub 2017 Oct 30.